Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
Esther González-López(Children's Cancer and Leukaemia Group), Pablo García‐Pavía(Universidad Francisco de Vitoria), Carolina Casado Robles(Hospital Universitario Puerta de Hierro Majadahonda), Clara Salas(Hospital Universitario Puerta de Hierro Majadahonda), F. Javier de Haro-del Moral(Hospital Universitario Puerta de Hierro Majadahonda), Gonzalo Guzzo-Merello(Hospital Universitario Puerta de Hierro Majadahonda), Enrique Lara‐Pezzi(Spanish National Centre for Cardiovascular Research), Belén Bornstein(Instituto de Investigaciones Biomédicas Sols-Morreale), Marta Cobo Marcos(Hospital Universitario Puerta de Hierro Majadahonda), Luis Alonso‐Pulpón(Hospital Universitario Puerta de Hierro Majadahonda), María Gallego‐Delgado(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 1,148
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k
A new staging system for cardiac transthyretin amyloidosis
|European Heart Journal|2017|740
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies
|Journal of the American College of Cardiology|2016|472